Prediction Held up AI assessment confidence: 95% certainty 3/5 debate potential 2/5

Nate Chang: Biotech IPO exits will slow down in 2019

Nate Chang · What’s with All the Bio M&A in 2019?: A Quick Take · Feb 28, 2019 · at 9:44

Nate Chang of Andreessen Horowitz forecasts capital markets activity and IPO pacing for biotech startups in 2019.

0:00 / 0:06exact quote · 6.7s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“I think we're gonna continue to see slightly slower pace in terms of IPO exits”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

Biotech IPO exits will continue at a slightly slower pace in 2019.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

The claim predicted that biotech IPO exits would continue at a slightly slower pace in 2019 compared to 2018. Across all tracking sources in the research notes (such as BioPharma Dive, Pearl Cohen, and EvaluatePharma), full-year 2019 biotech IPO counts and total proceeds were both lower than 2018 levels. For example, BioPharma Dive reported 47 biotech IPOs raising $4.7B in 2019 compared to 54 IPOs raising $5.4B in 2018, confirming a slightly slower pace of exits.

BioPharma Dive recorded 47 biotech IPOs ($4.7B) in 2019 versus 54 ($5.4B) in 2018.
Pearl Cohen data showed deal counts declined from 44 in 2018 to 39 in 2019 (~11% drop) and total capital raised dropped from $5.4B to $4.7B (~13% drop).
Across all research sources, the direction of year-over-year biotech IPO counts and total capital raised was consistently lower in 2019 than in 2018.

Checked against

[1] biopharmadive.com [2] biopharmadive.com [3] contractpharma.com [4] lifescivc.com [5] pearlcohen.com [6] fiercebiotech.com [7] fiercebiotech.com [8] renaissancecapital.com

"biotech IPOs" "2019" "2018" count raised "capital" OR "proceeds" "2018" "2019" "biotech IPOs" "BioPharma Dive" count OR raised "biotech" "IPO" "2018" "2019" total number raised billion OR million biotech IPOs 2018 2019 "raised" "BioWorld" OR "PitchBook" OR "EvaluatePharma" "2018" "2019" biotech IPO count raised total biotech IPO count capital raised 2018 vs 2019 "biotech IPOs" "2018" "2019" "EvaluatePharma" OR "Renaissance Capital" total raised count

assessed as of 2026-07-28

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

IPO exits

⚑ Spot an error? Report it

More from Nate Chang

Assertion Partly supported

Chang: Pharma Acquirers Strengthened Position During Q4 2018 Market Downturn

“I think the buyer psyche changed too, specifically in the fourth quarter where across all sectors of the market saw a downturn in, in trading, but I think the buyer universe actually strengthened across pharma.”

Nate Chang Feb 28, 2019 ▶ 2:39 What’s with All the Bio M&A in 2019?: A Quick Take

Insight

Chang: Pharma Buyers Acquire Biotech Startups to Control Drug Launch Messaging

“So I think part of it also is buyers want to control the launch and control the commercial message.”

Nate Chang Feb 28, 2019 ▶ 3:37 What’s with All the Bio M&A in 2019?: A Quick Take

Insight

Chang: Gene therapy modalities create moats providing sustained cash flows

“If you actually think about gene therapy and new technologies, they are creating the moat. Meaning, for example, Avexis and SMA, they are the, probably the leading gene therapy program out there, and they want to continue building that franchise and have not o…”

Nate Chang Feb 28, 2019 ▶ 4:17 What’s with All the Bio M&A in 2019?: A Quick Take

Opinion

Chang: Spark Therapeutics' Philadelphia manufacturing plant was a key acquisition asset

“If you actually look at Spark, it's, it definitely has its anchor in gene therapy, but I think the thing that gets underappreciated in biopharma is downstream capabilities, and so they have a manufacturing facility on Market Street in Philadelphia, and I think…”

Nate Chang Feb 28, 2019 ▶ 7:41 What’s with All the Bio M&A in 2019?: A Quick Take

Insight

Chang: Bio platforms require end-to-end operational solutions, not just discovery

“The platform is not just an enabling technology to source and discover new drugs, but it's also the breadth of end to end solutions for modality.”

Nate Chang Feb 28, 2019 ▶ 8:10 What’s with All the Bio M&A in 2019?: A Quick Take

Assertion Supported

Chang: Novartis acquired AAA and Endocyte to secure radioisotope supply chains

“He made two acquisitions in the radio label target oncology space. So with AAA and Endocyte being the most recent acquisition they were able to secure that supply chain for that specific radio isotope.”

Nate Chang Feb 28, 2019 ▶ 8:49 What’s with All the Bio M&A in 2019?: A Quick Take

Nate Chang: Biotech IPO exits will slow down in 2019

More from Nate Chang

Turn any episode into a week of clips.